| Literature DB >> 25940115 |
Nathlee Samantha Abbai1, Handan Wand2, Gita Ramjee3,4.
Abstract
BACKGROUND: The World Health Organization estimates that 536 million people aged 15-49 are infected with Herpes simplex virus type 2 (HSV-2), the causative agent of genital herpes. The aim of this study was to investigate the role of behavioral and demographic factors that contribute to the high HSV-2 sero-prevalence among women participating in a HIV prevention trial. The Methods for Improving Reproductive Health in Africa (MIRA) study assessed the effectiveness the latex diaphragm and lubricant gel on HIV prevention among women in South Africa and Zimbabwe. At screening an interviewer administered questionnaire on demographics and sexual behaviour was obtained. HSV-2 serum antibodies were detected using HerpeSelect™ ELISA IgG. Statistical analysis was performed using STATA release 12.0. This study was registered with ClinicalTrials.gov,number NCT00121459 on the 28th February 2007.Entities:
Mesh:
Year: 2015 PMID: 25940115 PMCID: PMC4423103 DOI: 10.1186/s13104-015-1093-0
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Socio-demographic, behavioural and biological data associated with Herpes Simplex Virus type −2 (HSV-2) in women that presented for screening
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
|
|
| |
|
| |||||
|
| 1430 (41%) | 1 | 1 | ||
|
| 1275 (37%) | 2.37 (2.00,2.81) | <0.001 | 1.82 (1.49,2.22) | <0.001 |
|
| 767 (22%) | 3.18 (2.55,3.95) | <0.001 | 3.49 (2.71,4.49) | <0.001 |
|
| |||||
|
| 191 (6%) | 1 | |||
|
| 3281 (94%) | 5.47 (4.01,7.43) | <0.001 | - | |
|
| |||||
|
| 904 (26%) | 1 | 1 | ||
|
| 2568 (74%) | 1.68 (1.43,1.98) | <0.001 | 1.26 (1.03,1.53) | 0.021 |
|
| |||||
|
| 325 (9% | 1 | |||
|
| 3147 (91%) | 1.72 (1.36,2.18) | <0.001 | - | |
|
| |||||
|
| 2073 (60%) | 1 | |||
|
| 1399 (40%) | 1.40 (1.19,1.63) | <0.001 | - | |
|
| |||||
|
| 528 (15%) | 1 | |||
|
| 2944(85%) | 1.54 (1.25,1.89) | <0.001 | - | |
|
| |||||
|
| 854 (25%) | 1 | 1 | ||
|
| 978 (28%) | 2.53 (2.10,3.10) | <0.001 | 1.89 (1.52,2.34) | <0.001 |
|
| 731 (21%) | 3.84 (3.10,4.82) | <0.001 | 2.30 (1.78,2.96) | <0.001 |
|
| 906 (26%) | 5.43 (4.33,6.82) | <0.001 | 2.48 (1.92,3.20) | <0.001 |
|
| |||||
|
| 2438 (71%) | 1 | |||
|
| 1034 (29%) | 1.03 (0.88,1.22) | 0.689 | - | |
|
| |||||
|
| 512 (15%) | 1 | 1 | ||
|
| 2960 (85%) | 2.31 (1.90,2.80) | <0.001 | 1.95 (1.54,2.48) | <0.001 |
|
| |||||
|
| 2692 (78%) | 1 | |||
|
| 780 (22%) | 1.40 (1.26,1.68) | 0.001 | - | |
|
| |||||
|
| 2041 (59%) | 1 | 1 | <0.001 | |
|
| 1431 (41%) | 7.38 (6.01,9.10) | <0.001 | 6.31 (5.06,7.88) | |
|
| |||||
|
| 3242 (94%) | 1 | |||
|
| 216 (6%) | 1.04 (0.76,1.43) | 0.786 | - | |
|
| |||||
|
| 3149 (91%) | 1 | |||
|
| 309 (9%) | 1.00 (0.77,1.30) | 0.999 | - | |
|
| |||||
|
| 3375 (97%) | 1 | |||
|
| 97 (3%) | 2.28 (1.29,4.05) | 0.005 | - | |
|
| |||||
|
| 1 | ||||
|
| 3403 (98%) | 1 | - | ||
|
| 69 (2%) | 1.48 (0.62,3.52) | 0.372 | ||
|
| |||||
|
| 2986 (86%) | 1 | - | ||
|
| 486 (14%) | 0.98 (0.69,1.39) | 0.895 | ||
|
| 1 | ||||
|
| 2500 (72%) | 1 | - | ||
|
| 972 (28%) | 0.94 (0.72,1.22) | 0.628 | ||
|
| |||||
|
| 3264 (94%) | 1 | - | ||
|
| 208 (6%) | 3.16 (1.73,5.74) | <0.001 | ||
|
| |||||
|
| 3160 (91%) | 1 | - | ||
|
| 312 (9%) | 1.32 (0.89,1.96) | 0.162 | ||
*CI: Confidence Interval.
1In vulva, vaginal or cervical.